Compare Mutual Funds
Risk
Very High
-
Rating
2.0
-
Min SIP Amount
₹1000
-
Expense Ratio
1.02
-
NAV
₹17.42
-
Fund Started
25 Nov 2022
-
Fund Size
₹91.88 Cr
-
Exit Load
-
-
1 Year
12.11%
-
3 Year
23.81%
-
5 Year
-
-
Equity
100.35%
-
Cash
-0.35%
-
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 21.38% |
Divi's Laboratories Ltd. | 9.73% |
Cipla Ltd. | 9.43% |
Dr. Reddy's Laboratories Ltd. | 9.40% |
Lupin Ltd. | 6.61% |
Torrent Pharmaceuticals Ltd. | 5.24% |
Laurus Labs Ltd. | 4.75% |
Aurobindo Pharma Ltd. | 4.28% |
Alkem Laboratories Ltd. | 4.21% |
Glenmark Pharmaceuticals Ltd. | 3.84% |
-
Name
-
-
Start Date
-
-
Description
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
-
Launch Date
25 Nov 2022
-
